The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease

Claudia Fabiani, Antonio Vitale, Donato Rigante, Giacomo Emmi, Giuseppe Lopalco, Gerardo Di Scala, Jurgen Sota, Ida Orlando, Rossella Franceschini, Bruno Frediani, Mauro Galeazzi, Florenzo Iannone, Gian Marco Tosi, Luca Cantarini

Research output: Contribution to journalArticle

Abstract

PURPOSE: To identify factors associated with sustained response to interleukin (IL)-1 inhibition among demographic, clinical and therapeutic data in patients with Behçet disease (BD).

METHODS: BD patients treated with anakinra or canakinumab were enrolled. Patients were divided into two groups according to the clinical response: group 1 included subjects showing a treatment duration of at least 52 weeks and no secondary inefficacy during the first follow-up year; the remaining patients were included in the group 2. Demographic, clinical and therapeutic data were analyzed to identify significant differences between groups.

RESULTS: Eighteen patients were included in group 1 and 18 patients in group 2. A better response to IL-1 inhibitors was significantly more common among patients with BD-related uveitis (p = 0.006) and patients with a longer disease duration (p = 0.03).

CONCLUSION: IL-1 blockade is effective in BD, especially in the subset of patients presenting eye involvement and in those with long-lasting disease.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalOcular Immunology and Inflammation
DOIs
Publication statusE-pub ahead of print - Aug 27 2018

Fingerprint

Interleukin 1 Receptor Antagonist Protein
Uveitis
Interleukin-1
Demography
canakinumab
Therapeutics

Cite this

The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease. / Fabiani, Claudia; Vitale, Antonio; Rigante, Donato; Emmi, Giacomo; Lopalco, Giuseppe; Di Scala, Gerardo; Sota, Jurgen; Orlando, Ida; Franceschini, Rossella; Frediani, Bruno; Galeazzi, Mauro; Iannone, Florenzo; Tosi, Gian Marco; Cantarini, Luca.

In: Ocular Immunology and Inflammation, 27.08.2018, p. 1-7.

Research output: Contribution to journalArticle

Fabiani, C, Vitale, A, Rigante, D, Emmi, G, Lopalco, G, Di Scala, G, Sota, J, Orlando, I, Franceschini, R, Frediani, B, Galeazzi, M, Iannone, F, Tosi, GM & Cantarini, L 2018, 'The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease', Ocular Immunology and Inflammation, pp. 1-7. https://doi.org/10.1080/09273948.2018.1511810
Fabiani, Claudia ; Vitale, Antonio ; Rigante, Donato ; Emmi, Giacomo ; Lopalco, Giuseppe ; Di Scala, Gerardo ; Sota, Jurgen ; Orlando, Ida ; Franceschini, Rossella ; Frediani, Bruno ; Galeazzi, Mauro ; Iannone, Florenzo ; Tosi, Gian Marco ; Cantarini, Luca. / The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease. In: Ocular Immunology and Inflammation. 2018 ; pp. 1-7.
@article{b9c2948a733d4444b640b612ddbff2de,
title = "The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Beh{\cc}et's Disease",
abstract = "PURPOSE: To identify factors associated with sustained response to interleukin (IL)-1 inhibition among demographic, clinical and therapeutic data in patients with Beh{\cc}et disease (BD).METHODS: BD patients treated with anakinra or canakinumab were enrolled. Patients were divided into two groups according to the clinical response: group 1 included subjects showing a treatment duration of at least 52 weeks and no secondary inefficacy during the first follow-up year; the remaining patients were included in the group 2. Demographic, clinical and therapeutic data were analyzed to identify significant differences between groups.RESULTS: Eighteen patients were included in group 1 and 18 patients in group 2. A better response to IL-1 inhibitors was significantly more common among patients with BD-related uveitis (p = 0.006) and patients with a longer disease duration (p = 0.03).CONCLUSION: IL-1 blockade is effective in BD, especially in the subset of patients presenting eye involvement and in those with long-lasting disease.",
author = "Claudia Fabiani and Antonio Vitale and Donato Rigante and Giacomo Emmi and Giuseppe Lopalco and {Di Scala}, Gerardo and Jurgen Sota and Ida Orlando and Rossella Franceschini and Bruno Frediani and Mauro Galeazzi and Florenzo Iannone and Tosi, {Gian Marco} and Luca Cantarini",
year = "2018",
month = "8",
day = "27",
doi = "10.1080/09273948.2018.1511810",
language = "English",
pages = "1--7",
journal = "Ocular Immunology and Inflammation",
issn = "0927-3948",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease

AU - Fabiani, Claudia

AU - Vitale, Antonio

AU - Rigante, Donato

AU - Emmi, Giacomo

AU - Lopalco, Giuseppe

AU - Di Scala, Gerardo

AU - Sota, Jurgen

AU - Orlando, Ida

AU - Franceschini, Rossella

AU - Frediani, Bruno

AU - Galeazzi, Mauro

AU - Iannone, Florenzo

AU - Tosi, Gian Marco

AU - Cantarini, Luca

PY - 2018/8/27

Y1 - 2018/8/27

N2 - PURPOSE: To identify factors associated with sustained response to interleukin (IL)-1 inhibition among demographic, clinical and therapeutic data in patients with Behçet disease (BD).METHODS: BD patients treated with anakinra or canakinumab were enrolled. Patients were divided into two groups according to the clinical response: group 1 included subjects showing a treatment duration of at least 52 weeks and no secondary inefficacy during the first follow-up year; the remaining patients were included in the group 2. Demographic, clinical and therapeutic data were analyzed to identify significant differences between groups.RESULTS: Eighteen patients were included in group 1 and 18 patients in group 2. A better response to IL-1 inhibitors was significantly more common among patients with BD-related uveitis (p = 0.006) and patients with a longer disease duration (p = 0.03).CONCLUSION: IL-1 blockade is effective in BD, especially in the subset of patients presenting eye involvement and in those with long-lasting disease.

AB - PURPOSE: To identify factors associated with sustained response to interleukin (IL)-1 inhibition among demographic, clinical and therapeutic data in patients with Behçet disease (BD).METHODS: BD patients treated with anakinra or canakinumab were enrolled. Patients were divided into two groups according to the clinical response: group 1 included subjects showing a treatment duration of at least 52 weeks and no secondary inefficacy during the first follow-up year; the remaining patients were included in the group 2. Demographic, clinical and therapeutic data were analyzed to identify significant differences between groups.RESULTS: Eighteen patients were included in group 1 and 18 patients in group 2. A better response to IL-1 inhibitors was significantly more common among patients with BD-related uveitis (p = 0.006) and patients with a longer disease duration (p = 0.03).CONCLUSION: IL-1 blockade is effective in BD, especially in the subset of patients presenting eye involvement and in those with long-lasting disease.

U2 - 10.1080/09273948.2018.1511810

DO - 10.1080/09273948.2018.1511810

M3 - Article

C2 - 30148652

SP - 1

EP - 7

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

SN - 0927-3948

ER -